EMA Panel Recommends Ibalizumab for Multidrug-Resistant HIV-1 EMA Panel Recommends Ibalizumab for Multidrug-Resistant HIV-1

A European Medicines Agency advisory panel recommended marketing authorization for ibalizumab (Trogarzo, Theratechnologies International) for the treatment of patients with multidrug-resistant HIV-1 infection.International Approvals

Source: Medscape Med Students Headlines - July 29, 2019 Category: Universities & Medical Training Tags: HIV/AIDS News Alert Source Type: news